The current standard treatment of Type 1 diabetes mellitus (T1DM) using subcutaneous administration of exogenous insulin is associated with daily stress and increased rate of severe hypoglycemic events due to suboptimal absorption and imprecise dosing [1]. This evidence concerns the gene INS and type 1 diabetes mellitus.